Although we did not observe an increase in eIF2α phosphorylation after SAL treatment in MS juveniles, this result was not surprising because MS by itself did not induce activation/phosphorylation of PERK or eIF2α. This evidence concerns the gene EIF2A and myeloid sarcoma.